GlassScriptPhysician profile
Stella Ortiz
NPI 1326557885
$325.16
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $286 · 2022: $39.56.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $119.30 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $103.07 | 2021 | |
| Glaxosmithkline, LLC. | $31.72 | 2021 | |
| Merck Sharp & Dohme LLC | $31.51 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $22.73 | 2022 | |
| Seagen INC. | $16.83 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stella Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.